Neurostimulation Growth Salvia BioElectronics is developing an implantable neuromodulation device for resistant migraine, presenting a high-potential clinical asset line that may attract partnerships, licensing, or co-development deals with large medical device players and specialty distributors.

Clinical Milestone Readiness The company is actively advancing clinical development and has recently secured significant funding, indicating momentum and a credible path to market that can be leveraged to engage potential investors, contract manufacturers, and clinical trial collaborators.

European US Footprint With operations in Europe and the United States and a founder base rooted in Eindhoven, Salvia offers a transatlantic gateway for partners seeking regulatory and market access along both regions, plus opportunities for joint ventures or regional manufacturing arrangements.

Funding Momentum A substantial Series B financing of 60 million USD enhances credibility for sales discussions with hospital systems and purchasing organizations, and can fund broader distribution channels, training programs, and after-sales service capabilities.

Diverse Application Potential Beyond migraine, Salvia is exploring cluster headache treatment, suggesting cross-selling opportunities to neuro musculoskeletal clinics, pain management centers, and neurology groups, as well as potential expansions into other neuromodulation indications.